Simple Summary Many patients with chronic-phase chronic myeloid leukemia (CP-CML)
treated with a tyrosine kinase inhibitor (TKI) experience disease progression and switch to …

Introduction: Tyrosine kinase inhibitors (TKI) have significantly improved treatment outcomes
for patients with newly diagnosed chronic myelogenous leukemia (CML) in chronic phase …

Introduction: Although current TKI options are often successful in managing CML-CP in early
lines of therapy, patients may experience issues related to tolerability or resistance to TKIs …

Background Tyrosine kinase inhibitors (TKI) can be safely discontinued in chronic phase
chronic myeloid leukemia (CP‐CML) patients who had achieved a sustained deep …

Background: ATP-competitive tyrosine kinase inhibitors (TKIs) are the current standard of
care for patients with chronic phase-chronic myeloid leukemia (CP-CML) in the first-line and …

Objectives SIMPLICITY (NCT01244750) is an observational study of patients with chronic‐
phase chronic myeloid leukemia (CP‐CML) in routine clinical practice receiving first‐line …

We sought to evaluate the outcomes of chronic phase (CP) chronic myeloid leukemia (CML)
in an era where five tyrosine kinase inhibitors (TKIs) are commercially available for the …

Background: Tyrosine kinase inhibitors (TKI) improve survival in patients with chronic
myeloid leukemia in chronic phase (CML-CP), who meet molecular milestones at specific …

Abstract Treatment of newly-diagnosed patients with chronic-phase chronic myeloid
leukemia (CP-CML) with tyrosine kinase inhibitors (TKIs) results in near-normal life …

Treatment-free remission leading to a sustained deep molecular response (DMR) following
the discontinuation of tyrosine kinase inhibitor (TKI) is a therapeutic goal in patients with …